Blueprint Medicines (NASDAQ:BPMC) and Palatin Technologies (NYSE:PTN) Head to Head Analysis

Palatin Technologies (NYSE:PTN) and Blueprint Medicines (NASDAQ:BPMC) are both manufacturing companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, profitability, institutional ownership and dividends.

Valuation & Earnings

This table compares Palatin Technologies and Blueprint Medicines”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palatin Technologies	$350,000.00	6.99	-$40.31 million	($1.55)	-0.06
Blueprint Medicines	$562.12 million	11.68	-$67.09 million	($2.47)	-41.17

Palatin Technologies has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Palatin Technologies, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Palatin Technologies has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.83, suggesting that its share price is 17% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Palatin Technologies and Blueprint Medicines, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palatin Technologies	0	0	0	0	0.00
Blueprint Medicines	0	4	13	1	2.83

Blueprint Medicines has a consensus price target of $126.56, indicating a potential upside of 24.46%. Given Blueprint Medicines’ stronger consensus rating and higher possible upside, analysts clearly believe Blueprint Medicines is more favorable than Palatin Technologies.

Profitability

This table compares Palatin Technologies and Blueprint Medicines’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Palatin Technologies	N/A	N/A	N/A
Blueprint Medicines	-13.19%	-77.49%	-20.84%

Insider & Institutional Ownership

11.5% of Palatin Technologies shares are held by institutional investors. 7.1% of Palatin Technologies shares are held by insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Palatin Technologies beats Blueprint Medicines on 9 of the 15 factors compared between the two stocks.

About Palatin Technologies

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company’s lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.